On 4/20/17, Safe Bulkers Inc's 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares (SB.PRC) will trade ex-dividend, for its quarterly dividend of $0.50, payable on 5/1/17. As a percentage of SB.PRC's recent share price of $19.80, this dividend works out to approximately 2.53%, so look for shares of SB.PRC to trade 2.53% lower — all else being equal — when SB.PRC shares open for trading on 4/20/17. On an annualized basis, the current yield is approximately 10.08%, which compares to an average yield of 7.25% in the "Shipping" preferred stock category, according to Preferred Stock Channel.As of last close, SB.PRC was trading at a 20.60% discount to its liquidation preference amount. The chart below shows the one year performance of SB.PRC shares, versus SB: Below is a dividend history chart for SB.PRC, showing historical dividends prior to the most recent $0.50 on Safe Bulkers Inc's 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares: In Tuesday trading, Safe Bulkers Inc's 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares ( SB.PRC) is currently down about 0.3% on the day, while the common shares ( SB) are trading flat.
HOST // Robert Powell
Retirement Planning Event
More from Stocks
CVS or Walgreens: Which Is the Better Dividend Stock?
While the two companies seem very similar on the surface, CVS and Walgreens are different stocks for different types of investors.
Apple Shares Grind Higher Amid Multiple Upgrades Ahead of March 25 Launch Event
Apple shares were indicated higher in pre-market trading Thursday after three analysts upgrades for the world's biggest tech company ahead of its much-anticipated launch event next week in Cupertino.
Fed Failures, Tariffs Tool, Levi's Goes Public, Trading Zuora: Market Recon
The Fed needs to buy short-term paper RIGHT NOW, and sell off longer-term paper.
Micron Technology Is Likely to Continue Trading Sideways in the Weeks Ahead
MU could rally Thursday but it will probably do very little to really improve the technical picture.
Biogen May Shed $16 Billion in Value After Scrapping Alzheimer's Drug Trial
Biogen shares plunged in pre-market trading Thursday after the biotech group dropped a late-stage trial for a key Alzheimer's disease drug.